• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs.犬玻璃体切除术后玻璃体内注射重组腺相关病毒(rAAV)后视网膜转导减少及转基因导向免疫原性增强。
Gene Ther. 2016 Jun;23(6):548-56. doi: 10.1038/gt.2016.31. Epub 2016 Apr 7.
2
Vitrectomy Before Intravitreal Injection of AAV2/2 Vector Promotes Efficient Transduction of Retinal Ganglion Cells in Dogs and Nonhuman Primates.玻璃体内注射AAV2/2载体前进行玻璃体切割术可促进犬和非人灵长类动物视网膜神经节细胞的高效转导。
Hum Gene Ther Methods. 2016 Jun;27(3):122-34. doi: 10.1089/hgtb.2016.034.
3
Stable rAAV-mediated transduction of rod and cone photoreceptors in the canine retina.稳定的重组腺相关病毒介导的犬视网膜视杆和视锥光感受器转导。
Gene Ther. 2003 Aug;10(16):1336-44. doi: 10.1038/sj.gt.3301990.
4
Amount of Green Fluorescent Protein in the Anterior Chamber after Intravitreal Injection of Triple-Mutated Self-Complementary AAV2 Vectors is Not Affected by Previous Vitrectomy Surgery.玻璃体内注射三重突变自互补 AAV2 载体后前房内绿色荧光蛋白的含量不受先前玻璃体切除术的影响。
J Nippon Med Sch. 2021;88(2):103-108. doi: 10.1272/jnms.JNMS.2021_88-203.
5
Improved Intravitreal AAV-Mediated Inner Retinal Gene Transduction after Surgical Internal Limiting Membrane Peeling in Cynomolgus Monkeys.食蟹猴手术性内界膜剥除术后玻璃体内注射腺相关病毒介导的视网膜内层基因转导的改善
Mol Ther. 2017 Jan 4;25(1):296-302. doi: 10.1016/j.ymthe.2016.10.008.
6
Highly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina.腺相关病毒载体向灵长类动物视网膜的高效递送
Hum Gene Ther. 2016 Aug;27(8):580-97. doi: 10.1089/hum.2016.085.
7
SubILM Injection of AAV for Gene Delivery to the Retina.用于视网膜基因递送的腺相关病毒亚内界膜注射
Methods Mol Biol. 2019;1950:249-262. doi: 10.1007/978-1-4939-9139-6_14.
8
Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.AAV2载体眼内给药途径决定体液免疫反应和治疗潜力。
Mol Vis. 2008 Sep 24;14:1760-9.
9
Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs.在犬类中使用玻璃体内注射腺相关病毒(AAV)载体进行光感受器靶向基因递送。
Gene Ther. 2016 Feb;23(2):223-30. doi: 10.1038/gt.2015.96. Epub 2015 Oct 15.
10
rAAV-compatible human mini promoters enhance transgene expression in rat retinal ganglion cells.rAAV 兼容的人类微型启动子增强大鼠视网膜神经节细胞中的转基因表达。
Exp Eye Res. 2024 Feb;239:109758. doi: 10.1016/j.exer.2023.109758. Epub 2023 Dec 18.

引用本文的文献

1
Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants.使用含视网膜下腺相关病毒的纤维蛋白水凝胶植入物进行视网膜基因治疗。
Sci Adv. 2025 Sep 5;11(36):eadv7922. doi: 10.1126/sciadv.adv7922.
2
The curious case of AAV immunology.腺相关病毒免疫学的奇特案例。
Mol Ther. 2025 May 7;33(5):1946-1965. doi: 10.1016/j.ymthe.2025.03.037. Epub 2025 Mar 27.
3
Intravitreal AAV2 gene delivery to feline retinal ganglion cells.玻璃体内注射腺相关病毒2型向猫视网膜神经节细胞递送基因。
Vision Res. 2025 Jan;226:108519. doi: 10.1016/j.visres.2024.108519. Epub 2024 Nov 16.
4
Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection.在玻璃体内注射 AAV2.7m8 之前和之后,对绵羊体内抗 AAV2 的中和抗体水平进行分析。
Gene Ther. 2024 Nov;31(11-12):580-586. doi: 10.1038/s41434-024-00495-5. Epub 2024 Oct 29.
5
Retention Rates of Genetic Therapies Based on AAV Serotypes 2 and 8 Using Different Drug-Delivery Materials.基于 AAV 血清型 2 和 8 采用不同给药材料的基因治疗的保留率。
Int J Mol Sci. 2024 Mar 26;25(7):3705. doi: 10.3390/ijms25073705.
6
AAV2-antiVEGFscFv gene therapy for retinal neovascularization.用于视网膜新生血管形成的腺相关病毒2-抗血管内皮生长因子单链抗体片段基因疗法。
Mol Ther Methods Clin Dev. 2023 Oct 29;31:101145. doi: 10.1016/j.omtm.2023.101145. eCollection 2023 Dec 14.
7
Tolerability and tropism of recombinant adeno-associated virus vectors in the African green monkey (Chlorocebus sabaeus) anterior chamber.重组腺相关病毒载体在非洲绿猴(Chlorocebus sabaeus)前房的耐受性和嗜性。
Gene Ther. 2023 Sep;30(9):714-722. doi: 10.1038/s41434-023-00407-z. Epub 2023 May 24.
8
Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans.在临床前动物模型和人类中复用腺相关病毒血清型特异性中和抗体。
Biomedicines. 2023 Feb 11;11(2):523. doi: 10.3390/biomedicines11020523.
9
From Bench to Bed: The Current Genome Editing Therapies for Glaucoma.从实验室到临床:青光眼的当前基因组编辑疗法
Front Cell Dev Biol. 2022 May 16;10:879957. doi: 10.3389/fcell.2022.879957. eCollection 2022.
10
Systemic and local immune responses to intraocular AAV vector administration in non-human primates.非人灵长类动物眼内注射腺相关病毒(AAV)载体后的全身和局部免疫反应。
Mol Ther Methods Clin Dev. 2022 Jan 22;24:306-316. doi: 10.1016/j.omtm.2022.01.011. eCollection 2022 Mar 10.

本文引用的文献

1
Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs.在犬类中使用玻璃体内注射腺相关病毒(AAV)载体进行光感受器靶向基因递送。
Gene Ther. 2016 Feb;23(2):223-30. doi: 10.1038/gt.2015.96. Epub 2015 Oct 15.
2
AAV-mediated and pharmacological induction of Hsp70 expression stimulates survival of retinal ganglion cells following axonal injury.腺相关病毒介导和药理学诱导的热休克蛋白70表达可刺激轴突损伤后视网膜神经节细胞的存活。
Gene Ther. 2015 Feb;22(2):138-45. doi: 10.1038/gt.2014.105. Epub 2014 Nov 27.
3
Differential targeting of feline photoreceptors by recombinant adeno-associated viral vectors: implications for preclinical gene therapy trials.重组腺相关病毒载体对猫光感受器的差异靶向作用:对临床前基因治疗试验的启示
Gene Ther. 2014 Oct;21(10):913-20. doi: 10.1038/gt.2014.65. Epub 2014 Jul 24.
4
Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach.用于通过视网膜下或玻璃体内途径将基因递送至犬视网膜的酪氨酸衣壳突变型腺相关病毒载体。
Gene Ther. 2014 Jan;21(1):96-105. doi: 10.1038/gt.2013.64. Epub 2013 Nov 14.
5
Immunology of AAV-Mediated Gene Transfer in the Eye.眼内 AAV 介导的基因转移的免疫学。
Front Immunol. 2013 Aug 30;4:261. doi: 10.3389/fimmu.2013.00261. eCollection 2013.
6
In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous.玻璃体腔给药治疗性外层视网膜的新型腺相关病毒的活体定向进化。
Sci Transl Med. 2013 Jun 12;5(189):189ra76. doi: 10.1126/scitranslmed.3005708.
7
Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa.一种用于治疗与MERTK相关的视网膜色素变性的腺相关病毒2型介导的基因治疗载体的临床前效力和安全性研究。
Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3.
8
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors.通过使用新型、衣壳突变的 AAV 载体经玻璃体腔递送来靶向感光细胞。
PLoS One. 2013 Apr 26;8(4):e62097. doi: 10.1371/journal.pone.0062097. Print 2013.
9
Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?优化重组腺相关病毒 2(AAV2)载体的衣壳:最后的门槛?
PLoS One. 2013;8(3):e59142. doi: 10.1371/journal.pone.0059142. Epub 2013 Mar 19.
10
Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.对腺相关病毒2型(AAV2)衣壳特定丝氨酸、苏氨酸或赖氨酸残基进行生物工程改造可提高其在体外和体内的转导效率。
Hum Gene Ther Methods. 2013 Apr;24(2):80-93. doi: 10.1089/hgtb.2012.194. Epub 2013 Mar 15.

犬玻璃体切除术后玻璃体内注射重组腺相关病毒(rAAV)后视网膜转导减少及转基因导向免疫原性增强。

Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs.

作者信息

Boyd R F, Boye S L, Conlon T J, Erger K E, Sledge D G, Langohr I M, Hauswirth W W, Komáromy A M, Boye S E, Petersen-Jones S M, Bartoe J T

机构信息

Department of Small Animal Clinical Sciences, Michigan State University, East Lansing, MI, USA.

Department of Ophthalmology, University of Florida College of Medicine, Gainesville, FL, USA.

出版信息

Gene Ther. 2016 Jun;23(6):548-56. doi: 10.1038/gt.2016.31. Epub 2016 Apr 7.

DOI:10.1038/gt.2016.31
PMID:27052802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4891289/
Abstract

Adeno-associated virus (AAV) vector-based gene therapy is a promising treatment strategy for delivery of neurotrophic transgenes to retinal ganglion cells (RGCs) in glaucoma patients. Retinal distribution of transgene expression following intravitreal injection (IVT) of AAV is variable in animal models and the vitreous humor may represent a barrier to initial vector penetration. The primary goal of our study was to investigate the effect of prior core vitrectomy with posterior hyaloid membrane peeling on pattern and efficiency of transduction of a capsid amino acid substituted AAV2 vector, carrying the green fluorescent protein (GFP) reporter transgene following IVT in dogs. When progressive intraocular inflammation developed starting 4 weeks post IVT, the study plan was modified to allow detailed characterization of the etiology as a secondary goal. Unexpectedly, surgical vitrectomy was found to significantly limit transduction, whereas in non-vitrectomized eyes transduction efficiency reached upwards to 37.3% of RGC layer cells. The developing retinitis was characterized by mononuclear cell infiltrates resulting from a delayed-type hypersensitivity reaction, which we suspect was directed at the GFP transgene. Our results, in a canine large animal model, support caution when considering surgical vitrectomy before IVT for retinal gene therapy in patients, as prior vitrectomy appears to significantly reduce transduction efficiency and may predispose the patient to development of vector-induced immune reactions.

摘要

基于腺相关病毒(AAV)载体的基因治疗是一种很有前景的治疗策略,可将神经营养转基因递送至青光眼患者的视网膜神经节细胞(RGC)。在动物模型中,玻璃体内注射(IVT)AAV后转基因表达的视网膜分布存在差异,玻璃体液可能是初始载体渗透的障碍。我们研究的主要目的是调查在犬类中,玻璃体后皮质切除术联合后玻璃体膜剥除术对携带绿色荧光蛋白(GFP)报告基因的衣壳氨基酸取代型AAV2载体在IVT后的转导模式和效率的影响。当IVT后4周开始出现进行性眼内炎症时,研究计划进行了修改,将详细确定病因作为次要目标。出乎意料的是,手术玻璃体切除术被发现会显著限制转导,而在未进行玻璃体切除术的眼中,转导效率高达RGC层细胞的37.3%。所发生的视网膜炎的特征是由迟发型超敏反应引起的单核细胞浸润,我们怀疑这是针对GFP转基因的。我们在犬类大动物模型中的结果表明,在考虑对患者进行视网膜基因治疗的IVT前进行手术玻璃体切除术时应谨慎,因为先前的玻璃体切除术似乎会显著降低转导效率,并可能使患者易发生载体诱导的免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dc/4891289/29ee99fb9d90/nihms780669f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dc/4891289/fbe58df2bb91/nihms780669f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dc/4891289/7f5ddc5ddea8/nihms780669f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dc/4891289/802abdfee034/nihms780669f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dc/4891289/29ee99fb9d90/nihms780669f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dc/4891289/fbe58df2bb91/nihms780669f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dc/4891289/7f5ddc5ddea8/nihms780669f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dc/4891289/802abdfee034/nihms780669f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4dc/4891289/29ee99fb9d90/nihms780669f4.jpg